Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | POLB | P06746 | 3/20 | 0.51 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.51 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.51 |
| ▸ | HRH3 | Q9Y5N1 | 7/20 | 0.49 |
| ▸ | MAOB | P27338 | 2/20 | 0.49 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | HRH2 | P25021 | 1/20 | 0.47 |
| ▸ | HRH1 | P35367 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3587105 | 0.89 | GPR119 (0.52) | KDM4EALDH1A1POLBTLR9TLR7 | |
| SCHEMBL3581553 | 0.87 | TLR9 (0.49) | TLR9TLR7HRH3MAOBEPHX2 | |
| SCHEMBL3583026 | 0.87 | TLR9 (0.49) | KDM4EALDH1A1POLBTLR9TLR7 | |
| SCHEMBL6476185 | 0.86 | KDM4E (0.65) | KDM4ESMN1; SMN2ALDH1A1POLBHRH3 | |
| SCHEMBL3579866 | 0.85 | HRH3 (0.63) | KDM4EALDH1A1POLBTLR9TLR7 | |
| SCHEMBL3579113 | 0.84 | KDM4E (0.55) | KDM4ESMN1; SMN2ALDH1A1TLR9TLR7 | |
| SCHEMBL3583116 | 0.84 | HRH3 (0.61) | SMN1; SMN2ALDH1A1POLBTLR9TLR7 | |
| SCHEMBL22638139 | 0.84 | FFAR4 (0.48) | SMN1; SMN2ALDH1A1POLBMAPTKMT2A | |
| SCHEMBL215303 | 0.83 | EPHX2 (0.52) | KDM4ESMN1; SMN2ALDH1A1EPHX2HRH2 | |
| SCHEMBL3580230 | 0.82 | HRH3 (0.59) | KDM4EALDH1A1POLBTLR9TLR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100075953-A1 | SUBSTITUTED PIPERAZINES, (1,4) DIAZEPINES, AND 2,5-DIAZABICYCLO (2.2.1) HEPTANES AS HISTAMINE H1 AND/OR H3 ANTAGONISTS OR HISTAMINE H3 REVERSE ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2010-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100075953-A1 | SUBSTITUTED PIPERAZINES, (1,4) DIAZEPINES, AND 2,5-DIAZABICYCLO (2.2.1) HEPTANES AS HISTAMINE H1 AND/OR H3 ANTAGONISTS OR HISTAMINE H3 REVERSE ANTAGONISTS | HRH3, HRH4, HRH2 | KDM4E 393/4885SMN1; SMN2 1112/4885ALDH1A1 1903/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.